Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
ClearPoint Neuro, Inc. stock logo
CLPT
ClearPoint Neuro
$11.26
+0.1%
$12.80
$5.11
$19.22
$315.17M0.93245,643 shs263,595 shs
Delcath Systems, Inc. stock logo
DCTH
Delcath Systems
$13.85
-2.2%
$14.43
$7.17
$18.23
$482.40M0.94390,525 shs699,443 shs
NeuroPace, Inc. stock logo
NPCE
NeuroPace
$10.41
-1.8%
$12.83
$5.45
$18.98
$341.45M2.03171,958 shs273,019 shs
Penumbra, Inc. stock logo
PEN
Penumbra
$256.75
-0.1%
$274.48
$148.00
$310.00
$9.94B0.5451,908 shs859,137 shs
13 Stocks Institutional Investors Won't Stop Buying Cover

Which stocks are hedge funds and endowments buying in today's market? Enter your email address and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying now.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
ClearPoint Neuro, Inc. stock logo
CLPT
ClearPoint Neuro
0.00%-2.43%-5.30%-18.29%+99.29%
Delcath Systems, Inc. stock logo
DCTH
Delcath Systems
0.00%-9.71%-14.03%-0.79%+71.84%
NeuroPace, Inc. stock logo
NPCE
NeuroPace
0.00%-5.96%-41.12%-15.37%+55.84%
Penumbra, Inc. stock logo
PEN
Penumbra
0.00%+0.18%-4.45%-10.26%+43.79%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
ClearPoint Neuro, Inc. stock logo
CLPT
ClearPoint Neuro
2.7314 of 5 stars
3.54.00.00.02.50.80.6
Delcath Systems, Inc. stock logo
DCTH
Delcath Systems
3.5547 of 5 stars
3.55.00.00.03.22.50.6
NeuroPace, Inc. stock logo
NPCE
NeuroPace
3.4762 of 5 stars
3.45.00.00.01.34.20.6
Penumbra, Inc. stock logo
PEN
Penumbra
4.6389 of 5 stars
3.45.00.03.71.52.51.9
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
ClearPoint Neuro, Inc. stock logo
CLPT
ClearPoint Neuro
3.00
Buy$25.00122.02% Upside
Delcath Systems, Inc. stock logo
DCTH
Delcath Systems
3.00
Buy$24.0073.29% Upside
NeuroPace, Inc. stock logo
NPCE
NeuroPace
2.83
Moderate Buy$15.5048.90% Upside
Penumbra, Inc. stock logo
PEN
Penumbra
2.88
Moderate Buy$302.4017.78% Upside

Current Analyst Ratings Breakdown

Latest PEN, DCTH, NPCE, and CLPT Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/28/2025
NeuroPace, Inc. stock logo
NPCE
NeuroPace
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$18.00
5/23/2025
Delcath Systems, Inc. stock logo
DCTH
Delcath Systems
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$24.00 ➝ $29.00
5/14/2025
NeuroPace, Inc. stock logo
NPCE
NeuroPace
JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOverweight ➝ Overweight$14.00 ➝ $16.00
5/14/2025
NeuroPace, Inc. stock logo
NPCE
NeuroPace
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Overweight$17.00 ➝ $17.00
4/24/2025
Penumbra, Inc. stock logo
PEN
Penumbra
UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$320.00 ➝ $330.00
4/24/2025
Penumbra, Inc. stock logo
PEN
Penumbra
BTIG Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy
4/24/2025
Penumbra, Inc. stock logo
PEN
Penumbra
Stifel Nicolaus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Set Price TargetBuy ➝ Buy$301.00 ➝ $318.00
4/24/2025
Penumbra, Inc. stock logo
PEN
Penumbra
Royal Bank Of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOutperform ➝ Outperform$315.00 ➝ $330.00
4/24/2025
Penumbra, Inc. stock logo
PEN
Penumbra
Truist Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$315.00 ➝ $330.00
4/24/2025
Penumbra, Inc. stock logo
PEN
Penumbra
Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOverweight ➝ Overweight$305.00 ➝ $315.00
4/24/2025
Penumbra, Inc. stock logo
PEN
Penumbra
Robert W. Baird
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOutperform ➝ Outperform$316.00 ➝ $325.00
(Data available from 6/23/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
ClearPoint Neuro, Inc. stock logo
CLPT
ClearPoint Neuro
$31.39M10.04N/AN/A$0.92 per share12.24
Delcath Systems, Inc. stock logo
DCTH
Delcath Systems
$37.21M12.96N/AN/A$2.15 per share6.44
NeuroPace, Inc. stock logo
NPCE
NeuroPace
$79.91M4.27N/AN/A$0.27 per share38.56
Penumbra, Inc. stock logo
PEN
Penumbra
$1.19B8.32$2.89 per share88.99$29.99 per share8.56
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
ClearPoint Neuro, Inc. stock logo
CLPT
ClearPoint Neuro
-$18.91M-$0.76N/AN/AN/A-64.51%-78.09%-51.33%8/6/2025 (Estimated)
Delcath Systems, Inc. stock logo
DCTH
Delcath Systems
-$26.39M-$0.50N/AN/AN/A-26.38%-29.44%-20.75%8/4/2025 (Estimated)
NeuroPace, Inc. stock logo
NPCE
NeuroPace
-$27.14M-$0.84N/AN/AN/A-29.42%-190.84%-25.08%8/12/2025 (Estimated)
Penumbra, Inc. stock logo
PEN
Penumbra
$14.01M$1.06242.2251.252.293.41%11.14%8.40%7/29/2025 (Estimated)

Latest PEN, DCTH, NPCE, and CLPT Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/13/2025Q1 2025
ClearPoint Neuro, Inc. stock logo
CLPT
ClearPoint Neuro
-$0.15-$0.22-$0.07-$0.22$8.21 million$8.49 million
5/13/2025Q1 2025
NeuroPace, Inc. stock logo
NPCE
NeuroPace
-$0.26-$0.21+$0.05-$0.21$21.85 million$22.52 million
5/8/2025Q1 2025
Delcath Systems, Inc. stock logo
DCTH
Delcath Systems
$0.10$0.03-$0.07$0.03$16.83 million$19.80 million
4/23/2025Q1 2025
Penumbra, Inc. stock logo
PEN
Penumbra
$0.66$0.83+$0.17$1.00$315.72 million$324.14 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
ClearPoint Neuro, Inc. stock logo
CLPT
ClearPoint Neuro
N/AN/AN/AN/AN/A
Delcath Systems, Inc. stock logo
DCTH
Delcath Systems
N/AN/AN/AN/AN/A
NeuroPace, Inc. stock logo
NPCE
NeuroPace
N/AN/AN/AN/AN/A
Penumbra, Inc. stock logo
PEN
Penumbra
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
ClearPoint Neuro, Inc. stock logo
CLPT
ClearPoint Neuro
N/A
3.53
2.57
Delcath Systems, Inc. stock logo
DCTH
Delcath Systems
N/A
15.95
14.61
NeuroPace, Inc. stock logo
NPCE
NeuroPace
2.46
6.63
5.70
Penumbra, Inc. stock logo
PEN
Penumbra
0.02
6.30
3.68

Institutional Ownership

CompanyInstitutional Ownership
ClearPoint Neuro, Inc. stock logo
CLPT
ClearPoint Neuro
30.08%
Delcath Systems, Inc. stock logo
DCTH
Delcath Systems
61.12%
NeuroPace, Inc. stock logo
NPCE
NeuroPace
78.83%
Penumbra, Inc. stock logo
PEN
Penumbra
88.88%

Insider Ownership

CompanyInsider Ownership
ClearPoint Neuro, Inc. stock logo
CLPT
ClearPoint Neuro
6.11%
Delcath Systems, Inc. stock logo
DCTH
Delcath Systems
17.94%
NeuroPace, Inc. stock logo
NPCE
NeuroPace
20.50%
Penumbra, Inc. stock logo
PEN
Penumbra
5.00%
CompanyEmployeesShares OutstandingFree FloatOptionable
ClearPoint Neuro, Inc. stock logo
CLPT
ClearPoint Neuro
11027.99 million26.28 millionOptionable
Delcath Systems, Inc. stock logo
DCTH
Delcath Systems
6034.83 million28.58 millionOptionable
NeuroPace, Inc. stock logo
NPCE
NeuroPace
17032.80 million26.08 millionOptionable
Penumbra, Inc. stock logo
PEN
Penumbra
4,50038.73 million36.79 millionOptionable

Recent News About These Companies

Penumbra completes enrolment in trial for pulmonary embolism

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
ClearPoint Neuro stock logo

ClearPoint Neuro NASDAQ:CLPT

$11.26 +0.01 (+0.09%)
Closing price 06/20/2025 04:00 PM Eastern
Extended Trading
$11.21 -0.05 (-0.48%)
As of 06/20/2025 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

ClearPoint Neuro, Inc. operates as a medical device company primarily in the United States. It develops and commercializes platforms for performing minimally invasive surgical procedures in the brain under magnetic resonance imaging guided interventions. The company offers ClearPoint system, an integrated system for the insertion of deep brain stimulation electrodes, biopsy needles, and laser catheters, as well as the infusion of pharmaceuticals into the brain. It has license and collaboration agreement with Clinical Laserthermia Systems AB; license and research agreement with Koninklijke Philips N.V., UCB Biopharma SRL, and University of California and San Francisco; and development and license agreement with NE Scientific, LLC. The company was formerly known as MRI Interventions, Inc. and changed its name to ClearPoint Neuro, Inc. in February 2020. ClearPoint Neuro, Inc. was incorporated in 1998 and is headquartered in Solana Beach, California.

Delcath Systems stock logo

Delcath Systems NASDAQ:DCTH

$13.85 -0.31 (-2.19%)
Closing price 06/20/2025 04:00 PM Eastern
Extended Trading
$14.45 +0.60 (+4.33%)
As of 06/20/2025 06:25 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Delcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphalan for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. Its clinical development program for HEPZATO is the FOCUS clinical trial for patients with metastatic hepatic dominant Uveal Melanoma to investigate objective response rate in metastatic uveal melanoma. It also provides HEPZATO as a stand-alone medical device under the CHEMOSAT Hepatic Delivery System trade name for Melphalan or CHEMOSAT for medical centers to treat a range of liver cancers in Europe. Delcath Systems, Inc. was incorporated in 1988 and is headquartered in New York, New York.

NeuroPace stock logo

NeuroPace NASDAQ:NPCE

$10.41 -0.19 (-1.79%)
Closing price 06/20/2025 04:00 PM Eastern
Extended Trading
$10.52 +0.11 (+1.05%)
As of 06/20/2025 08:00 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

NeuroPace, Inc. operates as a medical device company in the United States. The company develops RNS system, a brain-responsive neuromodulation system that delivers personalized, real-time treatment at the seizure source for treating medically refractory focal epilepsy. It also records continuous brain activity data and enables clinicians to monitor patients in person and remotely. Its RNS System includes RNS neurostimulator, cortical strip and depth leads, and Patient Remote Monitor, as well as other implantable and non-implantable accessories. The company sells its products to hospital facilities for initial RNS system implant procedures and for replacement procedures. NeuroPace, Inc. was incorporated in 1997 and is headquartered in Mountain View, California.

Penumbra stock logo

Penumbra NYSE:PEN

$256.75 -0.26 (-0.10%)
Closing price 06/20/2025 03:59 PM Eastern
Extended Trading
$256.87 +0.12 (+0.05%)
As of 06/20/2025 05:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Penumbra, Inc., together with its subsidiaries, designs, develops, manufactures, and markets medical devices in the United States and internationally. The company offers peripheral products, including the Indigo System for power aspiration of thrombus in the body; Lightning Flash, a mechanical thrombectomy system; Lightning Bolt 7, an arterial thrombectomy system; and CAT RX. It also provides access products, including guide catheters and the Penumbra distal delivery catheters under the Neuron, Neuron MAX Select, BENCHMARK, BMX96, BMX81, DDC, SENDit, and PX SLIM brands; Penumbra System, an integrated mechanical thrombectomy system comprising reperfusion catheters and separators, the 3D Revascularization Device, aspiration tubing, and aspiration pump under the Penumbra RED, JET, ACE, Max, 3D Revascularization Device, and Penumbra ENGINE brands; and neuro embolization coiling systems that includes the Penumbra Coil 400, a detachable coil that provides an alternative for the treatment of aneurysms and other complex lesions, as well as Penumbra SMART COIL, a detachable coil to treat patients with a wide range of neurovascular lesions; and POD400 and PAC400 brands. In addition, the company provides peripheral embolization products, such as Ruby Coil System consisting of detachable coils for peripheral applications; Penumbra LANTERN Delivery Microcatheter, a low-profile microcatheter with a high-flow lumen; POD (Penumbra Occlusion Device) System, a single device solution; and Packing Coil, a complementary device for use in other peripheral embolization products. Further, it offers an immersive 3D computer-based technology platform under the real immersive system brand; and neurosurgical tools, such as Artemis Neuro Evacuation Device for surgical removal of fluid and tissue from the ventricles and cerebrum. The company sells its products through direct sales organizations and distributors. Penumbra, Inc. was incorporated in 2004 and is headquartered in Alameda, California.